

Remarks

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Doran R. Pace

Patent Attorney

Registration No. 38,261

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRP/sl

Attachment: Marked-Up Version of Substituted Paragraphs

11/11/2010 10:00 AM

Marked-Up Version of Substituted Paragraphs

Paragraph on page 1, beginning at line 8:

Methylphenidate was first prepared as a mixture of the *erythro* [R^*S^*] and *threo* [R^*R^*] racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the *threo* diastereoisomer. It is now considered that it is the *d-threo* [or (R,R)] enantiomer that has the preferred therapeutic activity. Uses of this enantiomer are disclosed in PCT/GB96/01688 (International Publication No. WO 97/03671), PCT/GB96/01689 (International Publication No. WO 97/03672) and PCT/GB96/01690 (International Publication No. WO 97/03673), the contents of which are incorporated herein by reference.

Paragraph on page 4, beginning at line 14:

- 1) Resolve *dl-threo*-methylphenidate by the procedure described in the Example of PCT/GB97/00185 (International Publication No. WO 97/27176).